VGA
YARW

Vanguard Global Advisers’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Vanguard Global Advisers’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$600 Buy
+20
New +$583 ﹤0.01% 3656

Other funds holding YARW

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Global Advisers's YARW Position: Q1 2026 in Review

Vanguard Global Advisers opened a new position in Yarrow Bioscience, Inc. Common Stock (YARW) in Q1 2026: 20 shares worth $600. The stake represents ﹤0.01% of the portfolio and ranks #3656 among its holdings.

42 funds tracked by Wall St. Rank hold YARW as of Q1 2026.

  • Vanguard Global Advisers held 20 shares of Yarrow Bioscience, Inc. Common Stock worth $600 as of Q1 2026.
  • Yarrow Bioscience, Inc. Common Stock was a new Vanguard Global Advisers position in Q1 2026.
  • Yarrow Bioscience, Inc. Common Stock made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q1 2026, its #3656 holding.
  • 42 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q1 2026.

Based on Vanguard Global Advisers's 13F filing for Q1 2026, filed 8 May 2026.